De­fense De­part­ment en­lists Evotec to make new an­ti­body treat­ments for Mpox and oth­er pox­es

The De­part­ment of De­fense will pay up to $74 mil­lion to Evotec’s Seat­tle-based sub­sidiary to de­vel­op new an­ti­body treat­ments for or­thopoxvirus­es — a cat­e­go­ry of pathogens that in­cludes Mpox, for­mer­ly known as mon­key­pox, chick­en­pox and small­pox.

Per the con­tract, Just-Evotec Bi­o­log­ics will de­vel­op new an­ti­body ther­a­peu­tics up through first-in-hu­man tri­als. Evotec CEO Wern­er Lan­thaler de­clined to dis­close how many dis­eases the deal cov­ers or what dis­eases are in­clud­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER